QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly

QurCan Therapeutics, a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, recently announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS).

Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs.

QurCan Therapeutics is an OBIO® member, an alumnus of the BDSP™, CAAP® and HealthMINT™ programs and presented at the OBIO® Investment Summit.